title: Infliximab-Associated Immunomediated Hepatitis in Children With Inflammatory Bowel Disease.
abstract: Infliximab (IFX) is commonly used to induce and maintain remission in inflammatory bowel disease (IBD). We report the first 2 cases of children with ulcerative colitis who had normal liver transaminases before IFX and were diagnosed with immunomediated hepatitis after IFX induction. Both the cases had negative antibodies for antinuclear, smooth muscle, and liver kidney microsome, with 1 patient having positive autoimmune serology (dsDNA) and overlap primary sclerosing cholangitis. IFX was discontinued and transaminases normalized without steroid administration. Clinicians treating pediatric patients with IBD with IFX should be aware of IFX immunomediated hepatitis. This phenomenon is previously reported in adult patients with IBD. To our knowledge, these are the first cases reported in pediatric patients with IBD.
authors.affiliation: *Department of Gastroenterology and Hepatology, Phoenix Children's Hospital, Phoenix, AZ†Department of Gastroenterology, Hepatology and Nutrition, Texas Children's Hospital, Houston, TX.
authors.forename: Shikib
authors.initials: S
authors.lastname: Mostamand
authors.forename: Shauna
authors.initials: S
authors.lastname: Schroeder
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Schenkein
authors.forename: Tamir
authors.initials: T
authors.lastname: Miloh
mesh_terms: D000293:Adolescent; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002648:Child; D003093:Colitis, Ulcerative / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab / Q000009:adverse effects*; D008297:Male
chemical_list: D005765:Gastrointestinal Agents; D000069285:Infliximab